References
- LeaderBBacaQJGolanDEProtein therapeutics: a summary and pharmacological classificationNat Rev Drug Discov200871213918097458
- UsmaniSSBediGSamuelJSTHPdb: database of FDA-approved peptide and protein therapeuticsPLoS One2017127e018174828759605
- AgyeiDAhmedIAkramZIqbalHMDanquahMKProtein and peptide biopharmaceuticals: an overviewProtein Pept Lett20172429410128017145
- PutneySDBurkePAImproving protein therapeutics with sustained-release formulationsNat Biotechnol19981621531579487521
- MahmoodIGreenMDPharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteinsClin Pharmacokinet200544433134715828849
- SchellekensHBioequivalence and the immunogenicity of biopharmaceuticalsNat Rev Drug Discov20021645746212119747
- ScharrerIBrayGLNeutzlingOIncidence of inhibitors in haemophilia a patients – a review of recent studies of recombinant and plasma-derived factor VIII concentratesHaemophilia19995314515410444280
- GillesJGArnoutJVermylenJSaint-RemyJMAnti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restrictionBlood1993828245224617691260
- ZündorfIDingermannTPEGylation – a well-proven strategy for the improvement of recombinant drugsPharmazie201469532332624855821
- YangZWangJLuQPEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primatesCancer Res200464186673667815374983
- EkladiousIColsonYLGrinstaffMWPolymer–drug conjugate therapeutics: advances, insights and prospectsNat Rev Drug Discov Epub 2018 Dec 12
- BrownLRCommercial challenges of protein drug deliveryExpert Opin Drug Deliv200521294216296733
- RobinsonMFraserIMcKeeEScheckKChangLWillerthSMTransdifferentiating astrocytes into neurons using ASCL1 functionalized with a novel intracellular protein delivery technologyFront Bioeng Biotechnol2018617330525033
- di MarcoMShamsuddinSRazakKAOverview of the main methods used to combine proteins with nanosystems: absorption, bio-conjugation, and encapsulationInt J Nanomedicine20105374920161986
- RawatMSinghDSarafSSarafSNanocarriers: promising vehicle for bioactive drugsBiol Pharm Bull20062991790179816946487
- SalmasoSBersaniSSemenzatoACalicetiPNanotechnologies in protein deliveryJ Nanosci Nanotechnol200669–102736275317048478
- YuanHJiangS-PduY-ZMiaoJZhangX-GHuF-QStrategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticlesColloids Surf B Biointerfaces200970224825319185474
- LiuYKLinYLChenCHA unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene glycol: a nondisplaceable propertyBiotechnol Bioeng201110861318132721192002
- ChenCHLinYLLiuYKLiposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switchInt J Nanomedicine2012760762122346354
- LinYLLiuYKTsaiNMA lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cellsNanomedicine20128331832721704596
- WrobelICollinsDFusion of cationic liposomes with mammalian cells occurs after endocytosisBiochim Biophys Acta1995123522963047756338
- WongAWScalesSJReillyDEDNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleusJ Biol Chem200728231229532296317562704
- ThomasMKlibanovAMEnhancing polyethylenimine’s delivery of plasmid DNA into mammalian cellsProc Natl Acad Sci U S A20029923146401464512403826
- BenjaminsenRVMattebjergMAHenriksenJRMoghimiSMAndresenTLThe possible “proton sponge” effect of polyethylenimine (PEI) does not include change in lysosomal pHMol Ther201321114915723032976
- duLZhouJMengLThe pH-triggered triblock nanocarrier enabled highly efficient siRNA delivery for cancer therapyTherano stics201771434323445
- CharetteNVandeputteCStärkelPRas in digestive oncology: from molecular biology to clinical implicationsCurr Opin Oncol201426445446124849046
- TakahashiNYamadaYTaniguchiHClinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancerBMC Res Notes2014727124774510
- HicksJWartchowEMierauGGlycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatmentUltrastruct Pathol201135518319621910565
- GrabowskiGABartonNWPastoresGEnzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sourcesAnn Intern Med1995122133397985893
- CohenSCouéGBenoDKorensteinREngbersenJFBioreducible poly(amidoamine)s as carriers for intracellular protein delivery to intestinal cellsBiomaterials201233261462322014947
- CouéGFreeseCUngerREKirkpatrickCJEngbersenJFBioresponsive poly(amidoamine)s designed for intracellular protein deliveryActa Biomater2013946062607423237985
- KaczmarczykSJSitaramanKYoungHAHughesSHChatterjeeDKProtein delivery using engineered virus-like particlesProc Natl Acad Sci U S A201110841169981700321949376